206 related articles for article (PubMed ID: 27998192)
1. Current and evolving approaches for improving the oral permeability of BCS Class III or analogous molecules.
Dave VS; Gupta D; Yu M; Nguyen P; Varghese Gupta S
Drug Dev Ind Pharm; 2017 Feb; 43(2):177-189. PubMed ID: 27998192
[TBL] [Abstract][Full Text] [Related]
2. The Effect of Excipients on the Permeability of BCS Class III Compounds and Implications for Biowaivers.
Parr A; Hidalgo IJ; Bode C; Brown W; Yazdanian M; Gonzalez MA; Sagawa K; Miller K; Jiang W; Stippler ES
Pharm Res; 2016 Jan; 33(1):167-76. PubMed ID: 26286187
[TBL] [Abstract][Full Text] [Related]
3. pH-Dependent solubility and permeability criteria for provisional biopharmaceutics classification (BCS and BDDCS) in early drug discovery.
Varma MV; Gardner I; Steyn SJ; Nkansah P; Rotter CJ; Whitney-Pickett C; Zhang H; Di L; Cram M; Fenner KS; El-Kattan AF
Mol Pharm; 2012 May; 9(5):1199-212. PubMed ID: 22489626
[TBL] [Abstract][Full Text] [Related]
4. The use of biopharmaceutic classification of drugs in drug discovery and development: current status and future extension.
Lennernäs H; Abrahamsson B
J Pharm Pharmacol; 2005 Mar; 57(3):273-85. PubMed ID: 15807982
[TBL] [Abstract][Full Text] [Related]
5. The biopharmaceutics classification system (BCS): class III drugs - better candidates for BA/BE waiver?
Blume HH; Schug BS
Eur J Pharm Sci; 1999 Dec; 9(2):117-21. PubMed ID: 10620723
[TBL] [Abstract][Full Text] [Related]
6. Provisional classification and in silico study of biopharmaceutical system based on caco-2 cell permeability and dose number.
Pham-The H; Garrigues T; Bermejo M; González-Álvarez I; Monteagudo MC; Cabrera-Pérez MÁ
Mol Pharm; 2013 Jun; 10(6):2445-61. PubMed ID: 23675957
[TBL] [Abstract][Full Text] [Related]
7. BCS Biowaivers: Similarities and Differences Among EMA, FDA, and WHO Requirements.
Davit BM; Kanfer I; Tsang YC; Cardot JM
AAPS J; 2016 May; 18(3):612-8. PubMed ID: 26943914
[TBL] [Abstract][Full Text] [Related]
8. Impact of the US FDA "Biopharmaceutics Classification System" (BCS) Guidance on Global Drug Development.
Mehta MU; Uppoor RS; Conner DP; Seo P; Vaidyanathan J; Volpe DA; Stier E; Chilukuri D; Dorantes A; Ghosh T; Mandula H; Raines K; Dhanormchitphong P; Woodcock J; Yu LX
Mol Pharm; 2017 Dec; 14(12):4334-4338. PubMed ID: 29076742
[TBL] [Abstract][Full Text] [Related]
9. A modified physiological BCS for prediction of intestinal absorption in drug discovery.
Zaki NM; Artursson P; Bergström CA
Mol Pharm; 2010 Oct; 7(5):1478-87. PubMed ID: 20734997
[TBL] [Abstract][Full Text] [Related]
10. The FDA should eliminate the ambiguities in the current BCS biowaiver guidance and make public the drugs for which BCS biowaivers have been granted.
Benet LZ; Larregieu CA
Clin Pharmacol Ther; 2010 Sep; 88(3):405-7. PubMed ID: 20668447
[TBL] [Abstract][Full Text] [Related]
11. Prediction of solubility and permeability class membership: provisional BCS classification of the world's top oral drugs.
Dahan A; Miller JM; Amidon GL
AAPS J; 2009 Dec; 11(4):740-6. PubMed ID: 19876745
[TBL] [Abstract][Full Text] [Related]
12. Optimizing solubility and permeability of a biopharmaceutics classification system (BCS) class 4 antibiotic drug using lipophilic fragments disturbing the crystal lattice.
Tehler U; Fagerberg JH; Svensson R; Larhed M; Artursson P; Bergström CA
J Med Chem; 2013 Mar; 56(6):2690-4. PubMed ID: 23432334
[TBL] [Abstract][Full Text] [Related]
13. Comparing multilabel classification methods for provisional biopharmaceutics class prediction.
Newby D; Freitas AA; Ghafourian T
Mol Pharm; 2015 Jan; 12(1):87-102. PubMed ID: 25397721
[TBL] [Abstract][Full Text] [Related]
14. The complexity of intestinal permeability: Assigning the correct BCS classification through careful data interpretation.
Zur M; Hanson AS; Dahan A
Eur J Pharm Sci; 2014 Sep; 61():11-7. PubMed ID: 24262076
[TBL] [Abstract][Full Text] [Related]
15. Is the full potential of the biopharmaceutics classification system reached?
Bergström CA; Andersson SB; Fagerberg JH; Ragnarsson G; Lindahl A
Eur J Pharm Sci; 2014 Jun; 57():224-31. PubMed ID: 24075971
[TBL] [Abstract][Full Text] [Related]
16. Analysis of five active ingredients of Er-Zhi-Wan, a traditional Chinese medicine water-honeyed pill, using the biopharmaceutics classification system.
Cao X; Li H; Wang M; Ren X; Deng Y
Biomed Chromatogr; 2020 Feb; 34(2):e4757. PubMed ID: 31755125
[TBL] [Abstract][Full Text] [Related]
17. Modern bioavailability, bioequivalence and biopharmaceutics classification system. New scientific approaches to international regulatory standards.
Löbenberg R; Amidon GL
Eur J Pharm Biopharm; 2000 Jul; 50(1):3-12. PubMed ID: 10840189
[TBL] [Abstract][Full Text] [Related]
18. Regional intestinal drug permeation: biopharmaceutics and drug development.
Lennernäs H
Eur J Pharm Sci; 2014 Jun; 57():333-41. PubMed ID: 23988845
[TBL] [Abstract][Full Text] [Related]
19. Implementing the Biopharmaceutics Classification System in Drug Development: Reconciling Similarities, Differences, and Shared Challenges in the EMA and US-FDA-Recommended Approaches.
Cardot JM; Garcia Arieta A; Paixao P; Tasevska I; Davit B
AAPS J; 2016 Jul; 18(4):1039-46. PubMed ID: 27116020
[TBL] [Abstract][Full Text] [Related]
20. Using Physiologically Based Pharmacokinetic (PBPK) Modeling to Evaluate the Impact of Pharmaceutical Excipients on Oral Drug Absorption: Sensitivity Analyses.
Chow EC; Talattof A; Tsakalozou E; Fan J; Zhao L; Zhang X
AAPS J; 2016 Nov; 18(6):1500-1511. PubMed ID: 27520379
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
